K G Rendahl
Overview
Explore the profile of K G Rendahl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
209
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McGee Sanftner L, Rendahl K, Quiroz D, Coyne M, Ladner M, Manning W, et al.
Mol Ther
. 2001 May;
3(5 Pt 1):688-96.
PMID: 11356074
Viral delivery of neurotrophins or other therapeutic genes is an attractive option for treating retinal degeneration. Regulated expression of these genes in the retina is needed to aid in dose...
2.
Green E, Rendahl K, Zhou S, Ladner M, Coyne M, Srivastava R, et al.
Mol Ther
. 2001 Apr;
3(4):507-15.
PMID: 11319911
The goal of these experiments was to evaluate the potential of the fibroblast growth factor family members FGF-5 and FGF-18 to rescue photoreceptors from cell death in retinal degenerative disease....
3.
Lau D, McGee L, Zhou S, Rendahl K, Manning W, Escobedo J, et al.
Invest Ophthalmol Vis Sci
. 2000 Sep;
41(11):3622-33.
PMID: 11006261
Purpose: We evaluated adeno-associated virus (AAV)-mediated gene transfer of basic fibroblast growth factor (FGF-2) as a therapy for photoreceptor degeneration in a transgenic rat model of retinitis pigmentosa. Methods: Recombinant...
4.
Mandel R, Rendahl K, Snyder R, Leff S
Exp Neurol
. 1999 Sep;
159(1):47-64.
PMID: 10486174
Viral vectors have recently been used successfully to transfer genes and express different proteins in the brain. This review discusses the requirements to consider human clinical trials in which recombinant...
5.
Rendahl K, Leff S, Otten G, Spratt S, Bohl D, Van Roey M, et al.
Nat Biotechnol
. 1998 Aug;
16(8):757-61.
PMID: 9702775
Control of gene expression is important to gene therapy for purposes of both dosing and safety. In vivo regulation of gene expression was demonstrated following co-injection of two separate recombinant...
6.
Leff S, Rendahl K, Spratt S, Kang U, Mandel R
Exp Neurol
. 1998 Jun;
151(2):249-64.
PMID: 9628761
To investigate the biochemical requirements for in vivo L-DOPA production by cells genetically modified ex vivo in a rat model of Parkinson's disease (PD), rat syngeneic 9L gliosarcoma and primary...
7.
Mandel R, Rendahl K, Spratt S, Snyder R, Cohen L, Leff S
J Neurosci
. 1998 Jun;
18(11):4271-84.
PMID: 9592104
To achieve local, continuous L-DOPA delivery in the striatum by gene replacement as a model for a gene therapy for Parkinson's disease, the present studies used high titer purified recombinant...
8.
Rendahl K, Hall J
J Neurogenet
. 1996 Sep;
10(4):247-56.
PMID: 8923298
The no-on-transient-A gene was identified by independently isolated mutations causing visual-response abnormalities or courtship song defects. The nonA(diss) mutant is abnormal for all of these phenotypes. The pleiotropic effects of...
9.
Rendahl K, Gaukhshteyn N, Wheeler D, Fry T, Hall J
J Neurosci
. 1996 Feb;
16(4):1511-22.
PMID: 8778301
The Drosophila no-on-transient A (nonA) gene is involved in the visual behaviors and courtship song of the fly. The NONA polypeptide contains two copies of the RNA-recognition motif (RRM), a...
10.
Stanewsky R, Rendahl K, Dill M, Saumweber H
Genetics
. 1993 Oct;
135(2):419-42.
PMID: 8244005
We have performed a genetic analysis of the 14C region of the X chromosome of Drosophila melanogaster to isolate loss of function alleles of no-on-transient A (nonA; 14C1-2; 1-52.3). NONA...